320: In vivo activation of APCs with TLR ligands and tissue damage rather than amount of host APCs are critical factors that determine DLI-mediated GVL reactivity and GVHD in MHC-matched minor histocompatibility antigen (mHAg)-mismatched chimeras  by Radojcic, V. et al.
achieved in 81.2% (13/16) of responders, and occurred a median 10
(2-34.7) months after ECP. Nine cases (56.2%) had recurrent
cGvHD at 8.4 (3-19.3) months after achieving response and 1
(6.25%) had late primary disease relapse (6 months after ECP
initiation). Another non-responder had a late relapse. Factors as-
sociated with OR were younger age at cGvHD diagnosis and at
ECP initiation (50 years, P0.046), while that with CR was early
initiation of ECP within 18 months of cGvHD diagnosis
(P0.018). The 1-year, 2-year and 3-year post ECP initiation
survival rates were 66.7%, 38.1% and 23.8%. Types of cGvHD
onset and donor were associated with survival post ECP initiation
(P0.028 and P0.05). The patients with non-progressive onset
cGvHD and with HLA-MRD survived longer (1-year post ECP
initiation survival rates of 88.9% and 78.6%) than those with
progressive onset cGvHD and with HLA-MUD (50% and 33.3%).
However, OR and CR to ECP were not associated with prolonged
post ECP initiation survival. In summary, our results suggest that
ECP is an effective second-line treatment option for cGvHD
especially with early initiation. Progressive onset cGvHD and
HLA-MUD were associated with poor survival rates in patients
receiving ECP for cGvHD. Whether response to ECP would be
translated to higher survival requires a larger study.
Table
Characteristics Details
Sex: male/female (n/n) 9/12
Median age (median, range)
-- At day 0 42.6 (26.5-60.1) years
-- At cGvHD diagnosis 42.8 (26.8-60.4) years
-- At ECP initiation 43.4 (28-60.4) years
Type: HLA-MRD/-MUD/-
mismatched unrelated CBD
(n) 14/6/1
GvHD Prophylaxis (n)
-- Calcineurin inhibitor and
methotrexate 18
-- Calcineurin inhibitor and
methylprednisolone 2
-- Triple regimen 1
Acute GvHD (n) 19
-- Clinical Grade: I/II/III/IV 5/12/1/1
-- ECP for aGvHD 1
Chronic GvHD (n) 21
-- Onset: De novo/Progressive/
Recurrent (n) 1/13/7
-- CIBMTR Overall
Severity at ECP
initiation (n)
........Mild 2
........Moderate 11
........Severe 8
-- Maximum Grade (n)
........Limited 3
........Extensive 18
-- Median duration of ECP
(median, range)
10.8 (1.3-58.8)
months
-- Median follow-up time
after ECP initiation
(median,range)
15.5 (1.3-62.4)
months
-- Overall and complete
response to ECP by
CIBMTR Severity
........Mild (n (%)) 1 (50%), 1 (50%)
........Moderate (n (%)) 5 (45.4%), 4 (36.4%)
........Severe (n (%)) 5 (62.5%), 3 (37.5%)
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INTERACTION BETWEEN HOST NATURAL KILLER T CELLS AND DONOR
CD4CD25 TREG CELLS PROTECTS AGAINST GVHD AFTER TLI/ATS
HOST CONDITIONING AND ALLOGENEIC BONE MARROW TRANSPLAN-
TATION
Pillai, A.B.1, Dutt, S.1, George, T.I.1, Strober, S.A.1 1Stanford Uni-
versity School of Medicine, Stanford, CA.
The murine non-myeloablative regimen of total lymphoid irra-
diation (TLI) and anti-thymocyte serum (ATS) prevents acute
graft-versus host disease (aGVHD) and was recently successfully
applied for human hematolymphoid malignancies (Lowsky et al,
NEJM, 2005). To investigate GVHD protection, we transplanted
(BMT) 50 106 bone marrow cells and 60 106 splenocytes from
wild-type (WT), CD4-/-, IL-4-/-, or IL-10-/- C57BL/6 (H-2b) do-
nor mice into wild-type (WT) or natural killer (NK) T cell deﬁ-
cient J
18-/- BALB/c (H-2d) hosts following TLI/ATS. Controls
were WT BALB/c mice given 800cGy total body irradiation (TBI)
and ATS with BMT from WT C57BL/6 donors. TBI/ATS-con-
ditioned WT hosts given BMT from WT donors and TLI/ATS
conditioned WT hosts given BMT from CD4-/-, IL-4-/-, or IL-
10-/- donors developed aGVHD, with marked donor CD8 T cell
accumulation in liver, mesenteric lymph nodes (MLN), and colon
at day 6. Since GVHD protection depends on donor CD4 cells,
IL-4, and IL-10, we investigated the role of donor CD4 Tregs in
GVHD protection. TLI/ATS-conditioned WT hosts given BMT
from WT donors survived without aGVHD and demonstrated a
dramatic (p 0.01) ten-fold increase in the absolute number of
donor CD4CD25Foxp3Tregs in the spleen at day 6 after BMT
relative to TBI/ATS-conditioned WT hosts or TLI/ATS-condi-
tioned J
18-/- hosts that succumbed to aGVHD. These
CD4CD25Foxp3 Tregs secreted IL-4 and IL-10 and had the
GVHD suppression capacity of conventional CD4CD25 Tregs.
Pre-transplant adoptive transfer of sorted WT host invariant NK
T cells protected TLI/ATS-conditioned J
18-/- hosts from day 6
donor CD8 T cell accumulation and caused a signiﬁcant
(p  0.01) increase in the absolute number of donor
CD4CD25Foxp3 Tregs. Using congenic markers (CD45.1/
CD45.2), we found that these CD4Tregs arise from donor splenic
(peripheral) T cells after BMT. CD25 depletion of WT donor cells
before BMT into TLI/ATS-conditioned WT hosts or into TLI/
ATS-conditioned J
18-/- hosts given adoptive transfer of WT host
NK T cells resulted in loss of the donor CD4CD25Foxp3
Tregs subsets in the spleen, and signiﬁcantly increased day 6 donor
CD8 T cell accumulation in the host liver, MLN, and colon,
accompanied by lethal aGVHD. These studies show that host
invariant NK T cells are critical for GVHD protection and that
they can facilitate the expansion of donor CD4CD25Foxp3
Tregs, which protect TLI/ATS treated hosts from lethal GVHD
after allogeneic BMT.
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IN VIVO ACTIVATION OF APCS WITH TLR LIGANDS AND TISSUE DAM-
AGE RATHER THAN AMOUNT OF HOST APCS ARE CRITICAL FACTORS
THAT DETERMINE DLI-MEDIATED GVL REACTIVITY AND GVHD IN
MHC-MATCHED MINOR HISTOCOMPATIBILITY ANTIGEN (MHAG)-MIS-
MATCHED CHIMERAS
Radojcic, V.1, Skarica, M.1, Murphy, G.F.2, Luznik, L.1 1Division of
Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Cen-
ter at Johns Hopkins, Baltimore, MD; 2Department of Pathology,
Brigham and Women’s Hospital and Harvard Medical School, Boston,
MA.
We recently found that residual host CD11c DCs persist in the
skin of MHC-matched chimeras after myeloablative conditioning
and transplantation of T cell-repleted BM, and that those residual
host APCs are insufﬁcient for the induction of optimal DLI-
mediated alloreactivity (J Immunol.,2006). Since the latter obser-
vation in established C3H.SW3B6 chimeras differs from the
current paradigm in freshly irradiated MHC-matched chimeras,
we hypothesized that in established chimeras, beside host APCs
and donor T cells, the induction of DLI-mediated GVL reactivity
and GVHD requires two additional factors: (a) TLR-mediated
activation of APCs and (b) tissue damage. In vivo coadministration
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of TLR7 (imiquimod) and/or 9 (CpG1826) ligands with DLI
resulted in powerful DLI-mediated GVL reactivity (P0.02),
without clinical signs of GVHD in established C3H.SW3B6
chimeras. The effect was mediated by DLI-derived anti-mHAg-
speciﬁc T cells since adoptive transfer of B6 DLI to the syngeneic
B63B6 chimeras in the presence of TLR ligands did not result in
antitumor immunity. To examine the effects of tissue damage,
established C3H.SW3B6.SJL chimeras were lethally re-irradi-
ated and received C3H.SW BM together with puriﬁed donor
CD8 T cells. Consistent with previous observation, these chime-
ras did not develop severe GVHD despite the fact that skin DCs
were predominantly host-derived. However, if TLR7 ligand was
administered prior to re-irradiation and administration of donor
CD8 T cells, all chimeras developed severe skin and systemic
GVHD (P0.01). To determine whether the donor CD8 T cells
directly recognize host mHAgs and induce tissue damage, we
constructed chimeras using as a host B62m-/- mice in which host
DCs and parenchyma are unable to present MHC class I-restricted
peptides. We found no clinical signs of skin or systemic GVHD in
the re-irradiated C3H.SW3B62m-/- chimeras that received pu-
riﬁed donor CD8 T cells after pre-treatment with TLR7 ligand.
Our data suggest that in MHC-matched setting (1) despite the
presence of host DCs the TLR-mediated signaling is critical for
induction of DLI-mediated GVL reactivity in established chime-
ras; (2) induction of GVHD in established chimeras requires not
only donor T cells, host APCs and TLR ligands, but also tissue
damage. These requirements for GVL reactivity and/or GVHD in
established MHC-matched chimeras clearly differ from those in
freshly irradiated MHC-matched or in established MHC-mis-
matched chimeras.
321
SUCCESSFUL THERAPY OF STEROID-REFRACTORY ACUTE GRAFT-VER-
SUS HOST DISEASE WITH SEQUENTIAL ALEMTUZUMAB
Repp, R.1, Claviez, A.2, Schrauder, A.2, Schub, N.1, Gahn, B.1,
Gramatzki, M.1 1Division for Stem Cell Transplantation and Immu-
notherapy, 2nd Medical Department, University of Kiel, Kiel, Germany;
2Department of Pediatrics, University of Kiel, Kiel, Germany.
After allogeneic stem cell transplantation severe acute graft-
versus-host disease (GvHD) is the major limitation of this treat-
ment modality. While in acute GvHD addition of steroids to
immunosuppressive prophylaxis lead to a response rate of 30% to
70%, treatment options of steroid resistant acute GvHD are lim-
ited and no accepted standard for salvage therapy exists. Alemtu-
zumab (Campath-1H) is a commercially available humanized an-
tibody targeting the CD52 antigen, which is expressed on T-cells,
B-cells and on some monocyte derived dendritic cells. For years,
Alemtuzumab has been shown to be effective in GvHD prevention
when used in conditioning regimes, however infectious complica-
tions did limit this approach when routinely applied. In order to
evaluate efﬁcacy and safety of sequential alemtuzumab for severe
acute GvHD, ten patients with steroid-resistant acute GvHD of
grade III or IV involving the gut or/and liver were treated in our
Division. The initial three patients, all with advanced grade IV
GvHD of the liver and already receiving cyclosporine, mycophe-
nolate mofetil and high-dose steroids, were treated with up to 80
mg of alemtuzumab followed by additional 40 mg CD52 antibody
within the next four weeks. While dramatic clinical responses were
seen, such as a bilirubin level of 48 mg/dl returning to normal
within 6 weeks, virus reactivation and bacterial infections were
limiting this approach. Although pronounced lymphocyte deple-
tion seems inevitable for efﬁcacy, additional patients were treated
with lower doses of 20 to 30 mg Alemtuzumab, repeated approx-
imately every two weeks, while concomitant immunosuppressive
drugs could be tapered within 3 to 4 weeks. Acute GvHD improved
in all patients treated so far. A complete response of liver and gut
GvHD was seen in two patients, an additional patient developed a
vanishing bile duct syndrome but has no evidence of ongoing
GvHD. Another two patients are still on treatment with major
improvement of gut and liver-GVHD, respectively. Thus, alemtu-
zumab given sequentially in moderate doses shows promising ac-
tivity in severe, steroid refractory acute GvHD. However, moni-
toring for infectious complications, particularly by reactivated
viruses (CMV, adenovirus) is mandatory for months after treat-
ment.
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IN VIVO BIOLUMINESCENCE AND [18F]-FHBG MICROPET IMAGING
STUDIES OF HUMAN T CELL TRAFFICKING, EXPANSION, AND XENO-
GENEIC GRAFT-VERSUS-HOST-DISEASE FOLLOWING DIFFERENT
ROUTES OF HUMAN T CELL ADMINISTRATION
Rettig, M.P.1, Nervi, B.1, Ritchey, J.K.1, Prior, J.L.1,
Piwnica-Worms, D.1, Wang, H.L.1, Bauer, G.1, Walker, J.1,
Bonyhadi, M.L.2, Berenson, R.J.2, Nolta, J.1, DiPersio, J.F.1 1Wash-
ington University School of Medicine, St. Louis, MO; 2Xcyte Therapies,
Inc., Seattle, WA.
GVHD is the major cause of morbidity and mortality following
allogeneic hematopoietic stem cell transplantation. We previously
demonstrated that 60% of sublethally irradiated NOD/SCID-
2mnull mice develop lethal xenogeneic GVHD (X-GVHD) fol-
lowing retroorbital (r.o.) injection of 107 human T cells (huT).
However, we observed no X-GVHD when the huT were admin-
istered through the lateral tail vein (i.v.). In the current studies, we
used in vivo bioluminescence imaging (BLI) and [18F]FHBG mi-
croPET to evaluate why the route of huT cell administration
affected huT cell engraftment and the development of lethal
XGVHD in NOD/SCID-2mnull mice. We generated huT that
co-expressed chimeric CD34-thymidine kinase (CD34-TK; for
[18F]FHBG microPET) and click beetle red luciferase-egfp
(CBRluc-egfp; for BLI) genes by transducing the cells with two
retroviral vectors, selecting for CD34, and sorting for EGFP
(huTTK/CBR). As before, sub-lethally irradiated NOD/SCID-
2mnull mice injected i.v. with 107 huTTK/CBR failed to develop
lethal XGVHD, whereas 60% of mice injected r.o. developed
lethal XGVHD. Serial whole body BLI and [18F]FHBG micro-
PET revealed very different trafﬁcking patterns and expansion
proﬁles between the i.v. and r.o. routes of huT cell administration.
HuTTK/CBR cells injected i.v. immediately trafﬁcked to the lungs
and failed to expand during the ﬁrst three weeks after infusion. In
contrast, a signiﬁcant portion of the r.o.-injected cells remained in
the retroorbital cavity and trafﬁcked to secondary lymphoid organs
during the ﬁrst 7 days after huTTK/CBR cell infusion. This altered
trafﬁcking of the r.o.-injected cells was associated with a 10-fold
and 5-fold increase in the huTTK/CBR BLI signal and [18F]FHBG
standardized uptake value, respectively, during the ﬁrst 2 weeks
after huT cell infusion, with the huTTK/CBR cells accumulating in
the skin, lymph nodes, lungs and gut. This homing pattern and
strong BLI and [18F]FHBG signals of the r.o.-injected huTTK/CBR
cells remained until death from GVHD. Importantly, histological
examination of the GVHD target tissues revealed changes consis-
tent with human GVHD. Therefore, this NOD/SCID-2mnull
mouse model provides a system to study the pathophysiology of
acute GVHD induced by human cells and aids in the development
of more effective therapies for human GVHD.
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DAY 30 POST-TRANSPLANT ABSOLUTE LYMPHOCYTE AND NATURAL
KILLER CELL COUNT STRONGLY PREDICT OUTCOME AFTER ALLOGE-
NEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIG-
NANCY
Savani, B.N.1, Mielke, S.1, Rezvani, K.1, Yong, A.1, Shenoy, A.1,
Read, E.J.1, Hensel, N.1, Childs, R.1, Barrett, A.J.1 1Hematology
Branch, National Heart Lung and Blood Institute, National Institutes of
Health, Bethesda, MD.
One hundred and ﬁfty-seven patients with leukemia (80 CML,
48 AML, 29 ALL) received a T cell depleted myeloablative allo-
geneic stem cell transplant (SCT) (28 BM and 129 PB) from an
HLA-matched sibling between 09/1993-09/2005. Conditioning
consisted of TBI (12-13.6 Gy)  cyclophosphamide or combined
with ﬂudarabine. T cell dose ranged from 0.2 - 2  105CD3
cells/kg. GVHD prophylaxis was low dose cyclosporine (level 100-
200 ng/ml) in 103 and standard dose in 54. Patients without 
grade II acute GVHD received 1-2 donor lymphocyte infusions
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